Innovita Biological Technology Co., Ltd. (SHA:688253)
China · Delayed Price · Currency is CNY 56.92
+1.02 (1.82%)
At close: Sep 2, 2026
SHA:688253 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,539 | 4,070 | 4,948 | 3,403 | 3,241 | - | |
Market Cap Growth | 79.65% | -17.74% | 45.41% | 5.00% | - | - |
Enterprise Value | 5,784 | 2,227 | 3,088 | 1,921 | 1,811 | - |
Last Close Price | 55.90 | 29.95 | 35.33 | 24.12 | 22.82 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 150.45 | 28.17 | 20.04 | 19.56 | 21.51 | - |
Forward PE | 60.11 | 24.74 | 9.91 | - | - | - |
PS Ratio | 26.33 | 9.65 | 7.96 | 7.12 | 7.26 | - |
PB Ratio | 3.72 | 1.98 | 2.48 | 1.85 | 1.92 | - |
P/TBV Ratio | 3.76 | 2.01 | 2.49 | 1.85 | 1.93 | - |
P/FCF Ratio | 294.11 | 25.13 | 18.37 | 14.01 | 47.17 | - |
P/OCF Ratio | 166.51 | 21.08 | 16.20 | 13.10 | 25.64 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 20.20 | 5.28 | 4.97 | 4.02 | 4.06 | - |
EV/EBITDA Ratio | 117.13 | 14.55 | 11.93 | 9.56 | 16.30 | - |
EV/EBIT Ratio | 258.07 | 17.06 | 12.87 | 10.73 | 19.15 | - |
EV/FCF Ratio | 225.63 | 13.75 | 11.47 | 7.91 | 26.36 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Debt / EBITDA Ratio | 0.15 | 0.05 | 0.02 | 0.01 | 0.20 | 0.01 |
Debt / FCF Ratio | 0.28 | 0.05 | 0.02 | 0.01 | 0.34 | 0.03 |
Net Debt / Equity Ratio | -0.86 | -0.95 | -0.95 | -0.92 | -0.88 | -0.77 |
Net Debt / EBITDA Ratio | -38.07 | -12.69 | -7.29 | -8.43 | -13.32 | -3.89 |
Net Debt / FCF Ratio | -68.47 | -11.98 | -7.00 | -6.97 | -21.54 | -13.30 |
Asset Turnover | 0.13 | 0.19 | 0.29 | 0.24 | 0.33 | 0.41 |
Inventory Turnover | 1.70 | 1.91 | 2.43 | 2.06 | 2.94 | 1.88 |
Quick Ratio | 19.78 | 9.19 | 9.19 | 8.38 | 6.74 | 10.96 |
Current Ratio | 20.36 | 9.49 | 9.50 | 8.70 | 7.15 | 12.42 |
Return on Equity (ROE) | 2.50% | 7.14% | 12.87% | 9.85% | 12.41% | 17.09% |
Return on Assets (ROA) | 0.65% | 3.63% | 7.01% | 5.58% | 4.32% | 10.46% |
Return on Invested Capital (ROIC) | 8.96% | 108.53% | 168.04% | 87.88% | 45.40% | 91.02% |
Return on Capital Employed (ROCE) | 1.10% | 6.30% | 12.00% | 9.70% | 5.60% | 17.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.67% | 3.55% | 4.99% | 5.11% | 4.65% | - |
FCF Yield | 0.34% | 3.98% | 5.44% | 7.14% | 2.12% | - |
Dividend Yield | 0.81% | 1.50% | 1.58% | 1.66% | 0.73% | - |
Payout Ratio | 121.67% | 52.07% | 22.05% | 13.02% | 0.14% | 41.63% |
Buyback Yield / Dilution | 0.61% | 0.07% | -0.36% | -11.83% | -19.24% | -2.90% |
Total Shareholder Return | 1.42% | 1.57% | 1.23% | -10.17% | -18.52% | -2.90% |